Antonetti, Paolo
Fargnoli, Maria Concetta http://orcid.org/0000-0003-4629-7762
Porzio, Giampiero
Salvatore, Lisa
Filippi, Roberto
Ghidini, Michele
Nigro, Olga
Gelsomino, Fabio
Zurlo, Ina Valeria
Dell’Aquila, Emanuela
Lombardi, Pasquale
Keränen, Susana Roselló
Depetris, Ilaria
Giampieri, Riccardo
Morelli, Cristina
De Tursi, Michele
Di Pietro, Francesca Romana
Zanaletti, Nicoletta
Vitale, Pasquale
Garajova, Ingrid
Spinelli, Gian Paolo
Zoratto, Federica
Roberto, Michela
Petrillo, Angelica
Aimar, Giacomo
Cortellini, Alessio
Pensieri, Maria Vittoria
Ficorella, Corrado
Ferri, Claudio
Parisi, Alessandro
Article History
Received: 3 August 2021
Accepted: 21 October 2021
First Online: 15 November 2021
Declarations
:
: All patients alive at the time of data collection provided informed consent to participate to this retrospective observational non-interventional study. The procedures followed were in accordance with the precepts of Good Clinical Practice and the declaration of Helsinki. The study was approved by the respective local ethical committees on human experimentation of each institution, after previous approval by the coordinating center (Comitato Etico delle Province di L’Aquila e Teramo, protocol number 21, approved on July 16, 2020).
: All patients alive at the time of data collection provided an informed consent to participate to this retrospective observational non-interventional study.
: A.P. reported receiving advisory board fees from GSK. A.C. reported receiving consulting/advisory board fees from Astrazeneca, MSD, Roche and BMS; speakers’ fee from Novartis, Astellas, MSD, Astrazeneca. A.P. reported receiving fees from Eli-Lilly, MSD and Servier. R.G. reported receiving fees from Amgen and Servier and advisory board fees from Amgen, Servier, Bayer and Merck-Serono. GS reported receiving advisory board/Editorial fees from: Novartis, Servier, Teva, Bayer, Genetic, Epionpharma.